The key to reducing the individual and societal burden of age-related macular degeneration (AMD)-related vision loss is to be able to initiate therapies that slow or halt the progression at a point that will yield the EDNRB maximum benefit while…
The key to reducing the individual and societal burden of age-related macular degeneration (AMD)-related vision loss is to be able to initiate therapies that slow or halt the progression at a point that will yield the EDNRB maximum benefit while…